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Cardiovascular disease is the main cause of mortality worldwide, causing. 17.7 million deaths in 2015, corre-
sponding to 31% of all deaths worldwide. Of these, 6.7 mil-
lion were caused by myocardial infarction (MI), which is 
thus one of the main causes of cardiovascular disease deaths.1 
Knowledge about the molecular mechanisms that regulate the 
progression from MI to heart failure is incomplete, preclud-
ing the development of new therapeutic approaches. In recent 
years, the development of massive mRNA sequencing tech-
nologies has identified gene expression patterns associated 
with the development of heart failure.2 However, understand-
ing remains limited about post-transcriptional regulation and, 
more specifically, the role of RBPs (RNA binding proteins) in 
MI progression and in the development of heart failure.
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RBPs contain RNA-binding domains that enable them to 
bind RNA molecules and regulate different processes associated 
with RNA metabolism, including constitutive and alternative 
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Rationale: RBPs (RNA binding proteins) play critical roles in the cell by regulating mRNA transport, splicing, 
editing, and stability. The RBP SRSF3 (serine/arginine-rich splicing factor 3) is essential for blastocyst formation 
and for proper liver development and function. However, its role in the heart has not been explored.
Objective: To investigate the role of SRSF3 in cardiac function.
Methods and Results: Cardiac SRSF3 expression was high at mid gestation and decreased during late embryonic 
development. Mice lacking SRSF3 in the embryonic heart showed impaired cardiomyocyte proliferation and died 
in utero. In the adult heart, SRSF3 expression was reduced after myocardial infarction, suggesting a possible role 
in cardiac homeostasis. To determine the role of this RBP in the adult heart, we used an inducible, cardiomyocyte-
specific SRSF3 knockout mouse model. After SRSF3 depletion in cardiomyocytes, mice developed severe systolic 
dysfunction that resulted in death within 8 days. RNA-Seq analysis revealed downregulation of mRNAs encoding 
sarcomeric and calcium handling proteins. Cardiomyocyte-specific SRSF3 knockout mice also showed evidence 
of alternative splicing of mTOR (mammalian target of rapamycin) mRNA, generating a shorter protein isoform 
lacking catalytic activity. This was associated with decreased phosphorylation of 4E-BP1 (eIF4E-binding protein 
1), a protein that binds to eIF4E (eukaryotic translation initiation factor 4E) and prevents mRNA decapping. 
Consequently, we found increased decapping of mRNAs encoding proteins involved in cardiac contraction. 
Decapping was partially reversed by mTOR activation.
Conclusions: We show that cardiomyocyte-specific loss of SRSF3 expression results in decapping of critical mRNAs 
involved in cardiac contraction. The molecular mechanism underlying this effect likely involves the generation of 
a short mTOR isoform by alternative splicing, resulting in reduced 4E-BP1 phosphorylation. The identification 
of mRNA decapping as a mechanism of systolic heart failure may open the way to the development of urgently 
needed therapeutic tools.  (Circ Res. 2019;125:170-183. DOI: 10.1161/CIRCRESAHA.118.314515.)
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splicing, nucleo-cytoplasmic transport, intracellular localization, 
translation, and degradation.3 Loss of function of specific RBPs 
is associated with clinical manifestations, including neuropa-
thies, muscular atrophies, and cancer.3 In addition, recent studies 
show that some RBPs are crucial for proper cardiac function; 
loss of RBM20 (RNA-binding motif protein 20), TRBP (TAR 
RNA-binding protein), or RBFox2 (RNA-binding Fox-1 homo-
log 2) triggers the development and progression of dilated cardi-
omyopathy,4–7 whereas RBFox1 (RNA-binding Fox-1 homolog 
1) deficiency leads to hypertrophic cardiomyopathy.8
SRSF (serine/arginine-rich splicing factors, also known as 
SR proteins) are a family of highly conserved RBPs containing 
one or 2 RNA recognition motifs in their N-terminal region, 
followed by an SR domain formed of at least 50 amino acids 
with a serine and arginine content above 40%.9 SR proteins 
were originally identified as splicing factors, but several studies 
have demonstrated that they are multifunctional proteins that 
take part in many mRNA regulation pathways.10 SR proteins 
are localized both in the nucleus and the cytoplasm and regu-
late both the transport and stability of mRNA.11 Deficiency of 
particular SR proteins has been linked to several disease states, 
including heart disease. SRSF1, SRSF2, and SRSF10 are es-
sential for heart development and function. Loss of SRSF1 in 
the heart alters CaMKIIδ (calcium/calmodulin kinase IIdelta) 
splicing, which results in reduced phosphorylation of its target 
phospholamban, leading to calcium handling defects, hyper-
contraction, and death of the mice between 6 and 8 weeks of 
life.12 Cardiac-specific depletion of SRSF2 leads to excitation-
contraction defects and nonlethal dilated cardiomyopathy, 
associated with a decrease in RyR2 (ryanodine receptor 2) ex-
pression.13 Ubiquitous deletion of SRSF10 induces cardiac de-
velopmental defects that result in embryonic death at E15.5.14 
These defects are caused by alternative splicing of triadin, which 
results in reduced expression of both triadin and calsequestrin 2 
and lead to calcium handling defects in cardiomyocytes.14
Like other members of the SR family, SRSF3 regulates 
splicing of several mRNAs,15–17 mRNA cytoplasmic transport,11 
and mRNA localization.18 SRSF3 is essential for proper embry-
onic development. SRSF3-deficient embryos are unable to form 
blastocysts and die at the morula stage.19 Specific depletion of 
SRSF3 in the liver is not lethal, but mice present both embry-
onic and postnatal growth defects.20 As these mice get older, 
they develop hepatic carcinomas, mirroring the human disease, 
in which SRSF3 is also downregulated, in contrast to other can-
cer types.21 SRSF3 has also been reported to act as an onco-
gene in the liver by promoting cell proliferation.22 These studies 
establish the importance of SRSF3 for proper organ develop-
ment and function. However, unlike other RBPs, the function of 
SRSF3 in the heart has not been reported previously.
In this study, we show that SRSF3 is essential for heart 
development in mice and that SRSF3 expression in the adult 
heart is decreased in the remote myocardium after MI. Induced 
loss of SRSF3 in adult cardiomyocytes results in widespread 
changes in alternative splicing and decapping of mRNAs en-
coding contraction proteins and its subsequent degradation, 
leading to severe systolic dysfunction and death. We also show 
that SRSF3 regulates mTOR (mammalian target of rapamy-
cin) splicing, reducing the phosphorylation of 4E-BP1 (eIF4E-
binding protein 1) required to prevent mRNA decapping.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Nonstandard Abbreviations and Acronyms




mTOR mammalian target of rapamycin
NMD nonsense-mediated decay
RBP RNA Binding Protein




• RNA binding proteins regulate mRNA localization, stability, splicing, 
and activity.
• SRSF3 (serine/arginine splicing factor 3) plays a role in blastocyst for-
mation and in liver function.
What New Information Does This Article Contribute?
• The expression of SRF3 in the adult heart is essential for proper cardiac 
contraction and animal survival.
• Loss of SRSF3 results in expression of a smaller mTOR (mammalian 
target of rapamycin) isoform, which has no enzymatic capacity.
• SRSF3 prevents mRNA decapping and loss of SRSF3 results in in-
creased mRNA decapping and degradation of mRNAs encoding sarco-
meric proteins, which leads to systolic dysfunction.
RNA binding proteins play diverse roles in the cell, including mRNA 
transport, regulation of mRNA stability, and post-transcriptional 
mRNA modifications, among others. SRSF3 is an RNA binding 
protein that plays a role in embryonic development and in the 
liver. Its role in the heart was unknown. Using mice that lack 
SRSF3 specifically in cardiomyocytes, we found that SRSF3 is 
necessary for embryonic cardiomyocyte proliferation and heart 
development. In the adult heart, loss of SRSF3 causes severe 
cardiac contraction defects that lead to heart failure. We show 
that the loss of SRSF3 leads to decapping and degradation of 
mRNAs, specifically those encoding sarcomeric proteins. This is 
the main mechanism underlying cardiac dysfunction in our mice. 
We also show that the absence of SRSF3 causes aberrant splic-
ing of mTOR, producing a shorter isoform with reduced enzymatic 
activity, which is known to be necessary to prevent decapping. 
Based on these findings, it is tempting to speculate that mRNA 
decapping may have an important role in heart disease and that 
therapies aiming at modulating decapping may have a positive 
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RNA-Seq data are available from GEO (GSE123002; https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123002). The 
entire iCOUNT script for the (individual-nucleotide resolution 
cross-linking and immunoprecipitation) iCLIP analysis is available 
on github: https://github.com/tomazc/iCount. Materials used in this 
work will be made available on request to the corresponding author.
Mice
The SRSF3 knockout mice were originally generated by Dr Peter J. 
Nielsen.19 The neomycin cassette was removed by breeding SRSF3-
floxed mice with transgenic mice expressing CreERT2 under the 
polymerase II promoter (PolII-mER-Cre-mER). Treating these mice 
with low doses of tamoxifen generated an SRSF3-floxed mouse 
line that contained LoxP sites flanking SRSF3 exons 2 and 3. We 
performed 3 backcrosses with C57BL/6 to remove the Cre cassette 
and then crossed the resulting SRSF3-floxed mice with the cardiac-
specific Cre lines, Nkx2.5-Cre and αMHC-Cre. Both crosses re-
sulted in embryonic lethality, and lines were, therefore, maintained 
in heterozygosity for the SRSF3-floxed allele. In addition, we gen-
erated the cardiomyocyte-specific and inducible SRSF3 knockout 
mice by crossing SRSF3-floxed mice with αMHC-mER-Cre-mER 
mice. The resulting line was maintained in homozygosity. We used 
αMHC-mER-Cre-mER mice as negative controls. Genotyping was 
performed using the primers indicated in Online Table I.
Due to the effects of estrogens on the heart, only adult (2–3-month 
old) male mice were used for all experiments, to avoid potential ef-
fects of sex differences. Mice were euthanized by carbon dioxide as-
phyxiation. All procedures were approved by the ethics committees 
of the CNIC (Centro Nacional de Investigaciones Cardiovasculares) 
and the Regional Government of Madrid (PROEX 332-15). Animals 
were randomly assigned to groups. Researchers were blinded to the 
allocations.
Tamoxifen and Amino Acid Treatments
To activate the Cre recombinase in inducible knockout mice, SRSF3 
knockout and control mice were treated with 3 doses of 1 mg 4-hy-
droxytamoxifen on alternate days (1 dose/d). To prepare tamoxifen 
doses, 50 mg of 4-hydroxytamoxifen (H6278, Sigma) was diluted in 
500 µL 100% ethanol and stirred at 55°C for 1 hour, until completely 
dissolved. Preheated corn oil (4.5 mL) was then added, and the incuba-
tion continued with stirring at 55°C for a further hour. Once the tamoxi-
fen and corn oil were fully dissolved, the solution was maintained at 4°C 
until use. Just before injection, the solution was warmed and maintained 
at 37°C for 10 minutes. A total of 100 µL were injected intraperitoneal 
per mouse per day. To activate mTOR, mice were injected intraperito-
neal daily, for 7 days, starting on the day of the second tamoxifen injec-
tion, with 100 µL/g of a solution containing 6.0 g/L isoleucine, 12.0 g/L 
leucine, 7.2 g/L valine, and 6.04 g/L arginine in PBS (pH 7.4).23
Echocardiography
Transthoracic echocardiography was performed by blinded observers 
using a 40 MHz lineal transducer (Vevo 2100, VisualSonics). Mice 
were placed on a heating pad at 38.3ºC and lightly anesthetized with 
isoflurane in 100% oxygen. The Isoflurane concentration was adjust-
ed to maintain heart rate at 450 to 550 bpm.
Left ventricular (LV) systolic function was evaluated using the 
area/length method, with images acquired and recorded from 2-di-
mensional parasternal long axis views.24 Image analysis was per-
formed by blinded observers using Vevo 2100 analysis software 
(VisualSonics).
Embryo Extraction, In Situ Hybridization, and 
Histology
Embryos were extracted from C57BL/6, αMHC-Cre, or SRSF3-
floxed/αMHC-Cre mice at the stages indicated in the figures. In situ 
hybridization was performed on whole mount embryos (E9.5–E11.5) 
or 10 μm sections (E12.5–E14.5).25 The SRSF3 probe was designed 
to match the total length of the mRNA. Hematoxylin and eosin stain-
ing were performed on 5 μm sections according to standard protocols 
by the CNIC Histology Unit.
Gene Expression, Alternative Splicing, and Gene 
Ontology Analyses
Total RNA was extracted from left ventricles after 5 days of tamoxifen 
treatment using the RNeasy extraction kit (74104, Qiagen), including 
treatment with DNase. RNA sequencing was performed by the CNIC 
Genomics Unit. Libraries were prepared using polyA+ selection, and 
sequencing was performed using an Illumina-HiSeq 2500 platform, 
ensuring an average of 95 million paired-end reads per sample, with a 
minimum of 74 mol/L per sample. RNA-Seq analysis was performed by 
the CNIC Bioinformatics Unit. Fastq files containing the reads for each 
library were extracted and demultiplexed using the Casava v1.8.2 pipe-
line. Reads were preprocessed with a pipeline that used cutadapt v1.6 to 
remove Illumina adaptors, and FastQC to perform quality controls after 
each step. Gene expression was quantified using Kallisto v0.43.0,26 and 
the reference transcriptome was downloaded from Ensembl (Mus_mus-
culus.GRCm38.cdna.all.fa). One hundred bootstraps were performed to 
account for quantification uncertainty. Sleuth27 with default parameters 
was then used to normalize the data and perform differential expres-
sion analysis at the gene level. Genes with an adjusted P value <0.05 
and an absolute β >1 were considered to be differentially expressed for 
downstream enrichment analysis. Alternative splicing was analyzed us-
ing vast-tools to map reads against the mouse reference database and 
to perform differential splicing analysis.28,29 Gene ontology categories 
and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways 
were downloaded from the Enrichr website,28 and enrichment anal-
ysis of genes undergoing both differential expression or splicing was 
performed with one-sided Fisher tests and Benjamini-Hochberg False 
Discovery Rate correction using custom python scripts. RNA-Seq 
data were deposited in Gene Expression Omnibus (GSE123002).
Decapping Analysis
Decapped mRNA was quantified as previously described.30 Briefly, 
4 μg of total RNA was treated with DNase and ligated with the 
rP5_RND primer (Online Table II), which binds specifically to 5′ 
ends lacking the cap structure and presenting a phosphate group. 
Afterwards, 100 ng were used for cDNA synthesis, and polymerase 
chain reaction (qRT-PCR) was performed using the primers indicated 
in Online Table II. Values were normalized to total mRNA expression.
Statistical Analysis
Data were analyzed for statistical significance using the unpaired 
Student t test for experiments with 2 conditions and 1 variable, 1-way 
ANOVA followed by the Bonferroni post-test for more than 2 condi-
tions and 1 variable, and 2-way ANOVA followed by the Bonferroni 
post-test for analysis of multiple conditions and 2 variables, for nor-
mally distributed data, as indicated in each figure legend. The Mann-
Whitney test was used for non-normally distributed data. Data were 
analyzed using GraphPad Prism 5.0, and changes were considered 
significant at P<0.05. Correction for multiple comparisons was used 
for all analyses with more than one variable.
Results
SRSF3 Expression in the Heart Decreases With Age
In situ hybridization in embryos from E9.5 to E14.5 revealed 
strong SRSF3 staining in the heart from E12.5 (Figure 1A). 
For a more detailed analysis of changes in SRSF3 expression 
during heart development and in adulthood, we isolated hearts 
from mice ranging from E12.5 to 6 months of age and quan-
tified SRSF3 mRNA levels by qRT-PCR. SRSF3 expression 
was highest at E12.5 and decreased progressively during later 
embryonic stages and the postnatal period (Figure 1B). To i-
dentify the cardiac cell types expressing SRSF3 in the post-
natal heart, we performed an immunofluorescence analysis of 
heart sections from P1, P7, and 1-month-old mice. Clear stain-
ing for SRSF3 was detected in cardiomyocyte nuclei, as well 
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SRSF3 Downregulation Following MI Is Associated 
With Inclusion of Exon 4
To determine whether SRSF3 could be altered in heart di-
sease, we measured its expression after MI in the region 
remote from the infarct (Figure 2A–2E). Both mRNA and 
protein SRSF3 expression was downregulated after MI 
(Figure 2B and 2C), suggesting a possible role in cardiac 
homeostasis. Published evidence shows that SRSF3 is regu-
lated by the alternative splicing of exon 4, inclusion of which 
leads to degradation of the mRNA through nonsense-medi-
ated decay (NMD; Figure 2A).31 qRT-PCR analysis revealed 
increased SRSF3 exon 4 inclusion in infarcted hearts, sug-
gesting a role of this mechanism in the regulation of SRSF3 
after MI (Figure 2D).
Figure 1. SRSF3 (serine/arginine splicing factor 3) expression in the heart decreases with age. A, In situ hybridization for SRSF3 performed at different 
embryonic stages, either in whole mount (Left set: E9.5, E10.5, and E11.5) or 10 μm sections (Right set: E12.5, E13.5, and E14.5). The region including the 
developing heart is shown at high magnification to the right of each whole-embryo view. B, qRT-PCR (polymerase chain reaction) analysis of SRSF3 mRNA 
expression (exons 3–5) normalized to Gapdh expression in hearts extracted from C57BL/6 mice at different time points. Data are shown as mean±SEM; 
n=3–4 mice per group. **P<0.01, ***P<0.001 vs E12.5, 1-way ANOVA followed by the Bonferroni multiple comparison test. C, Immunofluorescence analysis of 
hearts isolated from C57BL/6 mice at different ages using anti-SRSF3 (red), anti-TroponinT (green), and DAPI (blue). M, month; Bars, A, 1 mm (whole mount, 
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SRSF1 has been shown to regulate SRSF3 expression by 
promoting exon 4 skipping.31 The post-MI increase in exon 4 in-
clusion thus prompted us to investigate whether SRSF1 expres-
sion was also affected. Western blot analysis showed decreased 
SRSF1 expression after MI (Figure 2E). These results suggest 
that the decrease in SRSF1 expression may favor the inclusion 
of SRSF3 exon 4, leading to SRSF3 downregulation after MI.
SRSF3 Cardiac Depletion During Embryonic 
Development Is Lethal
To investigate the role of SRSF3 in the heart, we developed 
several cardiac-specific knockout mouse models. We first 
crossed SRSF3-floxed mice with transgenic mice expressing 
Cre recombinase under the control of the Nkx2.5 promoter. 
No transgenic animals bearing both the Nkx2.5 promoter and 
the floxed SRSF3 allele were born (Table), suggesting that 
early SRSF3 depletion during heart development is embry-
onically lethal. To limit the recombination to cardiomyocytes 
and later developmental stages, we crossed SRSF3-floxed 
mice with mice expressing Cre recombinase under the αMHC 
promoter, which also was embryonically lethal (Table). 
Hematoxylin and eosin staining showed a reduction in my-
ocardium thickness in embryonic hearts lacking SRSF3 ex-
pression (Figure 3A and 3B). Previous reports that show that 
SRSF3 promotes proliferation22 prompted us to investigate if 
cardiomyocyte proliferation was affected in these animals; we 
were unable to detect any cardiomyocytes with positive stain-
ing for the mitosis marker phospho-histone H3 in myocardium 
lacking SRSF3 expression (Figure 3C and 3D). These results 
suggest that SRSF3 expression in cardiomyocytes is essential 
for cell proliferation, proper heart development, and subse-
quent embryo survival.
Cardiac-Specific SRSF3 Knockout Mice Develop 
Severe and Fatal Contraction Defects
To investigate the role of SRSF3 in the adult heart, we devel-
oped a cardiac-specific tamoxifen-inducible knockout mouse 
line by crossing SRSF3-floxed and αMHC-mER-Cre-mER 
mice (SRSF3 knockout). SRSF3 depletion occurred rap-
idly, with a strong decline already observed on the first day 
after tamoxifen administration (Online Figure IA and IB). 
Immunofluorescence analysis confirmed that SRSF3 was de-
pleted only in cardiomyocytes, although recombination was 
incomplete, and some cardiomyocytes were still positive for 
SRSF3 expression (Online Figure IC).
Unlike SRSF2 and SRSF1 cardiac-specific knockout 
mice, which either have a normal lifespan (SRSF2) or sur-
vive for several weeks after birth (SRSF1),12,13 no SRSF3 
knockout mice survived beyond 8 days after SRSF3 depletion 
(Figure 4A). Echocardiography analysis of SRSF3 knockout 
mice 5 days after tamoxifen administration revealed a pro-
nounced reduction in left ventricular ejection fraction and a 
strong increase in LV systolic volume (Figure 4B and 4C and 
Online Movie I), suggesting that these mice develop severe 
contraction defects that lead to death. No significant changes 
were observed in LV diastolic volume, likely due to the short 
Figure 2. SRSF3 (serine/arginine splicing factor 3) is downregulated after myocardial infarction (MI) by alternative splicing. A, Schematic of the 
SRSF3 mRNA isoforms. The yellow box represents alternative exon 4. B and C, Analysis by qRT-PCR (polymerase chain reaction; B) and Western blot (C) 
of SRSF3 mRNA (exons 3–5 normalized to Gapdh) and protein expression in the remote myocardium of mouse hearts 28 days after induction of MI by left 
coronary artery ligation. MW markers are indicated. D, qRT-PCR analysis of the SRSF3 NMD (nonsense-mediated decay) isoform in the remote myocardium, 
normalized to total SRSF3 mRNA expression. E, Western blot analysis of SRSF1 protein expression in the remote myocardium. Data in B and D are 
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lifespan after SRSF3 knockout (Figure 4D and Online Table 
III). Systolic dysfunction was accompanied by an increase in 
Nppb (natriuretic peptide B) and Acta1 gene expression in 
SRSF3 knockout hearts (Figure 4E and 4F). Together, these 
results demonstrate that the loss of SRSF3 in cardiomyocytes 
leads to severe cardiac dysfunction and premature death.
SRSF3 Depletion Results in Downregulation of 
Contraction-Related Genes
To investigate the mechanism underlying the contraction de-
fects in SRSF3 knockout mice, we performed RNA-Seq in 
control and knockout hearts 5 days after tamoxifen admin-
istration. We found significant expression changes in several 
genes, both upregulated and downregulated (Online Table IV 
and Online Figure IIA). Gene ontology analysis showed a de-
crease in contraction-related genes and an increase in genes 
related to protein maturation and transport in the ER and to 
the immune response (Online Figure IIB and IIC). qRT-PCR 
analysis to confirm these results revealed that the decreased 
expression of sarcomeric genes was already evident 2 days 
after SRSF3 depletion (Figure 5A–5F). Protein levels of 
SERCA2A (sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2a) and MYH (myosin heavy chain) were unchanged 
until day 5 after tamoxifen administration (Figure 5G), sug-
gesting that cardiac function is preserved until the expres-
sion of contraction proteins decreases. To determine whether 
the downregulation of sarcomeric gene expression was due 
to general RNA degradation associated with apoptosis, we 
first measured the number of apoptotic cardiomyocytes in 
control and SRSF3 knockout mice 5 days after the last ta-
moxifen injection. We found a very low number of TUNEL+ 
(terminal deoxynucleotidyl transferase dUTP nick-end label-
ing) cardiomyocytes overall and no differences between both 
mouse lines (Online Figure IIIA). We observed a very mild 
decline in total RNA integrity 5 days after the last tamoxifen 
injection in knockout mice, which, in any case, takes place 
much later than the decrease of sarcomeric mRNA, which is 
already evident at day 2 (Online Figure IIIB, Figure 5A–5F). 
We found no differences in the apoptosis markers Raptor and 
Fas, and only a mild decrease in Bcl2 mRNA expression at 
late time points in SRSF3 knockout mice that was not ac-
companied by a decrease in Bclxl (Online Figure IIIC–IIIF). 
Therefore, the decrease in sarcomeric gene expression pre-
cedes early signs of apoptosis, which would start a few days 
later. Early stages of cell death would be in agreement with 
the induction of genes associated with the immune response 
observed in knockout mice 5 days after tamoxifen treatment 
(Online Figure IIB).
SERCA2A Overexpression Partially Rescues 
Cardiac Contraction in SRSF3 Knockout Mice
Reduced expression of SERCA2A in cardiomyocytes is 
strongly associated with heart failure,32 and SERCA2A over-
expression has been shown to improve cardiac function in sev-
eral animal models.33,34 To determine whether the decreased 
expression of cardiac contraction proteins, specifically 
SERCA2A, is responsible for the severe systolic dysfunc-
tion in SRSF3 knockout mice, we overexpressed SERCA2A 
in control and knockout animals using serotype 9 adeno-as-
sociated viruses (AAV9-SERCA2A). AAV9-LUC, carrying 
the luciferase reporter gene, was used as a negative control. 
Viruses were injected into control and SRSF3 knockout mice 
1 week before tamoxifen induction to ensure transgene over-
expression in advance of the loss of SERCA2A expression. 
SERCA2A overexpression was confirmed by western blot 5 
days after tamoxifen induction (Figure 6A).
We found that AAV9-SERCA2A significantly im-
proved survival of SRSF3 knockout mice (Figure 6B). 
Echocardiography analysis of cardiac function showed a mild 
but significant improvement in left ventricular ejection frac-
tion in mice overexpressing SERCA2A, and increased stroke 
volume (Figure 6C and 6D and Online Table V). Although this 
improvement was far from a full recovery, we conclude that 
the downregulation of SERCA2A is responsible, at least in 
part, for the contraction defects observed in SRSF3 knockout 
mice. Full recovery would likely require overexpression of ad-
ditional genes involved in cardiac contraction whose expres-
sion was reduced in the knockout mice.
SRSF3 Binds to the Untranslated Region of 
Contraction-Related mRNAs
To gain further insight into the mechanisms underlying the 
contraction defects in SRSF3 knockout mice, we looked for 
direct SRSF3 target mRNAs in cardiac tissue. For this, we per-
formed iCLIP on mouse neonatal cardiomyocytes transfected 
with modified RNA encoding an SRSF3-GFP (green fluores-
cent protein) chimera, and analyzed the distribution of iCLIP 
binding sites along different regions of the genes detected to be 
expressed in the previous RNA-Seq analysis (Online Table VI). 
SRSF3 showed a tendency to bind exons, particularly in cod-
ing regions (Online Figure IVA). Genes with SRSF3-enriched 
exons were associated with post-transcriptional processing and 
insulin signaling, whereas SRSF3-bound untranslated regions 
(UTRs) were present in genes associated with muscle contrac-
tion (Online Figure IVB and IVC). These analyses identified 
SRSF3 binding to several contraction-related mRNAs, in-
cluding MYBPC3 (myosin-binding protein C), TNNT2 (tro-
ponin T2), and TNNC1 (troponin C1; Online Table VI). The 
SRSF3 consensus motif derived from iCLIP peaks (significant 
X-links) was identical to the bona fide SRSF3 motif (CNYC) 
and was independent of the bound transcript region (whole 
transcript versus UTR; Online Figure VID and VIE).
Based on these results, we decided to study whether SRSF3 
could increase the stability of an mRNA by binding to its 3′-
UTR. To test this hypothesis, we used a stability assay based 
on a protein-RNA binding system present in the MS2 virus 
(Online Figure VA).35 P19 cells were transfected with MS2-
CP or MS2-CP-SRSF3 and Rluc8 (containing 8 repeats of the 
Table. Genotype of the Srsf3 Allele in the Offspring of Nkx2.5-Cre/Srsf3wt/fl and 
αMHC-Cre/Srsf3wt/fl Mice
SRSF3 Genotype Nkx2.5-Cre αMHC-Cre
wt/wt 33 (30.84%) 29 (29.29%)
floxed/wt 74 (69.16%) 70 (70.71%)
floxed/floxed 0 (0%) 0 (0%)
Total mice 107 99
Number and percentage of mice born in the first 20 litters obtained from 
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MS2-CP binding loop in the 3′UTR region of R-Luc) or Rluc0 
(containing no loops). Cells were treated with Actinomycin 
D, and R-Luc expression and enzymatic activity were meas-
ured at different time points after treatment. Expression of the 
MS2-CP-SRSF3 chimera had no effect either on luciferase 
mRNA stability (Online Figure VB and VC) or on protein ac-
tivity (Online Figure VD and VE). These results suggest that 
the downregulation of contraction-related genes after SRSF3 
depletion is independent of the binding of this RBP to the 3′-
UTR in the target mRNAs.
SRSF3 Depletion Leads to a Late Induction of NMD
SRSF3 has been shown to promote the inclusion of alternative 
exons that lead to the appearance of premature stop codons, trig-
gering mRNA degradation by NMD.36 Therefore, we explored 
whether NMD was responsible for the degradation of cardiac 
contraction-related mRNAs in SRSF3 knockout hearts. qRT-
PCR analysis of SRSF3 knockout mouse hearts showed induced 
expression of the NMD genes SMG1, SMG8, SMG9, SMG6, 
and RBM8A (Online Figure VIA–VIE). In agreement with these 
results, we also observed an increased proportion of the NMD 
isoform of SERCA2A (Online Figure VIF). However, most of 
these changes took place 4 or 5 days after tamoxifen treatment. 
Thus, although SRSF3 depletion in the heart induces NMD, it is 
unlikely that this mechanism mediates the early downregulation 
of contraction-related mRNAs already observed at day 2.
SRSF3 Regulates mTOR Alternative Splicing
Given that SRSF3 regulates alternative splicing,15–17 we 
looked for alternative splicing changes in our RNA-Seq data. 
Figure 3. Loss of SRSF3 (serine/arginine splicing factor 3) in the developing heart results in embryonically lethal heart defects. A and B, Hematoxylin 
and eosin (H&E) staining in sections of αMHC-Cre embryos (A) and SRSF3-floxed/αMHC-Cre embryos (B) at E9.5. The boxed areas in A and B are shown at 
high magnification in A′ and B′, illustrating the cell deficit in the developing ventricular wall of SRSF3-floxed/αMHC-Cre embryos. Bar, 250 µm (A and B), 50 
μm (A′ and B′). C and D, Immunofluorescence analysis in sections of αMHC-Cre embryos (C) and SRSF3-floxed/αMHC-Cre embryos (D) at E10.5, using anti-
phospho-Histone H3 (red), anti-TroponinT (green), and Dapi (blue). Arrows indicate cardiomyocytes positive for phospho-histone H3; the developing SRSF3-
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We identified changes in different types of alternative splic-
ing events, ranging from alternative usage of splice donor and 
acceptors to intron retention (Online Figure VIIA and Online 
Table VII). Cassette exons were the event type showing the 
highest proportion (about 7%) of significant changes. There 
were more than twice as many exons with decreased inclusion 
rates than exons with increased inclusion, suggesting that the 
loss of SRSF3 mainly results in exon skipping. Skipped exons 
were associated with cytoskeletal organization and transcrip-
tion, whereas retained introns affected genes associated with 
the regulation of transcription and translation, which could 
eventually contribute to the decreased expression of contrac-
tion-related genes (Online Figure VIIB and VIIC).
To determine whether the observed splicing changes were 
directly mediated by SRSF3, we identified SRSF3 iCLIP bind-
ing sites (significant X-links) on regulated exons and flanking 
regions that were potentially involved in splicing regulation 
(Online Figure VIIIA–VIIID and Online Tables VIII and IX). 
We found that SRSF3 bound preferentially to skipped exons, 
suggesting that the lack of direct SRSF3 binding results in 
exclusion of these exons. In contrast, for included exons, we 
observed increased SRSF3 binding in the flanking introns and 
exons, suggesting that SRSF3 acts here as an inhibitor of exon 
inclusion, for example, by promoting skipping (Online Figure 
VIIIA and VIIIB). For skipped introns, SRSF3 binding sites 
were over-represented in the intronic region and its flanking 
Figure 4. Cardiac-specific SRSF3 (serine/arginine splicing factor 3) knockout (KO) mice develop severe and fatal contraction defects. Deletion of 
SRSF3 in cardiomyocytes was induced in inducible SRSF3 KO mice by 3 hydroxytamoxifen injections on alternate days (post-induction days 0, 2, and 4). 
A, Survival curves for hydroxytamoxifen-injected control and SRSF3 KO mice. B–D, Echocardiography analysis of left ventricular ejection fraction (B), left 
ventricular end-systolic volume (C), and left ventricular end-diastolic volume (D); ***P<0.001 SRSF3 KO vs Control, ###P<0.001 vs Basal; 2-way ANOVA 
followed by the Bonferroni post-test. E and F, qRT-PCR (polymerase chain reaction) analysis of the cardiac expression of BNP (E) and Acta1 (F) mRNA over 5 
days post-induction. Data are shown as mean±SEM. n=5–13 mice per group. Two-way ANOVA followed by Bonferroni post-test. *P<0.05, ***P<0.001 SRSF3 
KO vs Control. ###P<0.001 vs day 1. ACTA1 indicates actin alpha 1; BNP, brain natriuretic peptide; LVEDV, left ventricular end diastolic volume; LVEF, left 
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exons, indicating that SRSF3 promotes the retention of these 
introns. On the contrary, introns showing increased retention 
(inclusion) in knockout mice did not show a significant asso-
ciation with SRSF3 binding sites, suggesting that they may 
be an indirect consequence of SRSF3 deletion (Online Figure 
VIIIC and VIIID).
Among other changes, we found a significant change in 
alternative splicing of mTOR mRNA, which was bound to 
SRSF3 (Online Tables VI–IX). More specifically, we found 
that retention of mTOR intron 5 in SRSF3 knockout mice 
led to a decrease in the full-length mTOR isoform and in turn 
favored the expression of a much shorter isoform containing 
only the first 5 exons of the gene. This short isoform lacks 
the mTOR kinase domain (Figure 7A). We next checked 
whether this alternative splicing change was already present 
from day 2 after tamoxifen administration, when mRNAs 
related to contraction begin to decrease. Western blot anal-
ysis of SRSF3 knockout hearts confirmed loss of the long 
isoform and gain of the short isoform at day 2 after the in-
duction of recombination (Figure 7B). This was associated 
with decreased phosphorylation of the mTOR targets AKT 
and 4E-BP1 (Figure 7B).37,38
Figure 5. SRSF3 (serine/arginine splicing factor 3) depletion results in downregulation of contraction-related genes. A–F, qRT-PCR (polymerase chain 
reaction) analysis of the cardiac expression of SERCA2A (A), RyR2 (B), MYBPC3 (C), TNNT2 (D), MYH7 (E), and MYH6 (F) mRNA in control and SRSF3 KO 
mice over 5 days post tamoxifen induction. Data are shown as mean±SEM;. n=5–13 mice per group. *P<0.05, **P<0.01, and ***P<0.001 for SRSF3 knockout 
(KO) vs control; #P<0.05, ##P<0.01, ###P<0.001 vs day 1; 2-way ANOVA followed by the Bonferroni post-test. G, Western blot analysis of MYH and 
SERCA2A protein expression in the heart over 5 days post tamoxifen induction. MYBPC3 indicates myosin-binding protein C3; MYH6, myosin heavy chain 6; 
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SRSF3 Depletion Induces Decapping of 
Contraction-Related mRNAs
The phosphorylation state of 4E-BP1 determines its inter-
action with eIF4E (eukaryotic translation initiation factor 
4E); hypo-phosphorylation leads to a stronger interaction, 
inhibiting eIF4E and preventing its binding to mRNA cap 
structures.38 Thus, a potential consequence of reduced 4E-
BP1 phosphorylation is increased mRNA decapping due to 
increased accessibility of the mRNA cap. Decapping of an 
mRNA induces its degradation,39 and analysis of the decap-
ping status of contraction-related mRNAs in SRSF3 knock-
out hearts revealed an increase in the proportion of decapped 
SERCA2A, RyR2, MYBPC3, and MYH7 mRNAs. Although 
the largest increase was observed at day 5 post tamoxifen ad-
ministration, increased decapping could be detected as early 
as day 2 (Figure 7C–7F). These results indicate that the down-
regulation of contraction-related genes observed after cardiac 
SRSF3 depletion might be due to an increase in mRNA decap-
ping activity.
To determine whether loss of mTOR activity was respon-
sible for the increased decapping of these genes, we overacti-
vated mTOR in SRSF3 knockout mice by treating them with 
amino acid injections starting on the second day of tamoxifen 
administration and for a total of 7 days. As shown in Online 
Figure IX, mTOR activation reduced decapping of some sar-
comeric genes but did not rescue systolic function overall. 
Together, these results suggest that the loss of mTOR activ-
ity is partially responsible for the decapping of at least some 
sarcomeric genes. However, it is likely that additional mecha-
nisms controlled by SRSF3 are dysregulated in the knockout 
mice and contribute to their pathological phenotype.
Discussion
In this study, we describe for the first time the role of SRSF3 
in the embryonic and adult heart. The expression pattern of 
SRSF3 in the heart correlates with cell proliferation, with the 
highest expression levels found in the developing heart. This 
finding is in line with the suggestion that it functions as a pro-
to-oncogene by promoting cell cycle progression and tumor-
igenesis.22 These results are also consistent with the role that 
SRSF3 plays during early embryo formation and with the em-
bryonic lethality we observed in constitutive cardiac-specific 
SRSF3 knockout mice, which died in utero, likely due to defi-
cient cardiomyocyte proliferation.
A key finding of our study is that loss of SRSF3 in adult 
cardiomyocytes leads to decapping and degradation of mRNAs 
encoding proteins involved in cardiac contractility, resulting in 
severe systolic dysfunction and death. mRNA decapping has 
mostly been viewed as a process for RNA recycling once it 
is no longer useful.39,40 However, recent studies have begun 
to link mRNA decapping to disease progression. Specifically, 
the expression of the decapping protein DCP1A (decapping 
Figure 6. SERCA2A overexpression partially rescues systolic dysfunction in SRSF3 (serine/arginine splicing factor 3) knockout (KO) mice. A, Western 
blot analysis of SERCA2A protein expression in hearts of tamoxifen-induced control and SRSF3 KO mice administered AAV9 encoding luciferase (LUC) or 
SERCA2A (see Methods for details). B, Survival curve for SRSF3 KO mice treated either with AAV9-SERCA2A (dashed line; n=7) or AAV9-LUC as a control 
(continuous line; n=4). The x axis indicates time (days) after the last tamoxifen injection. C and D, Echocardiography analysis of left ventricular ejection 
fraction (C) and stroke volume (D) in mice treated as in A. *P<0.05 for AAV9-SERCA2A vs AAV9-LUC; ###P<0.001 for SRSF3 KO vs control; 2-way ANOVA 
followed by the Bonferroni post-test. AAV9 indicates adeno-associated virus 9; LVEF, left ventricular ejection fraction; SERCA2A, sarcoplasmic/endoplasmic 
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mRNA 1A) has been associated with melanoma progression,41 
and the tumor suppressor PNRC1 (proline-rich nuclear re-
ceptor coactivator 1) has been shown to act by recruiting the 
decapping complex, thus hampering ribosomal RNA matura-
tion.42 Given that SRSF3 expression is associated with tumor 
progression,22,43 it would be interesting to assess if mRNA de-
capping is affected in cancer types in which SRSF3 is essential 
for progression; this would provide new insights into tumor 
progression mechanisms and possible therapeutic targets.
The role of mRNA decapping in heart homeostasis and 
disease is virtually unknown. Our study provides the first ev-
idence of the importance of decapping deregulation in the 
adult heart. Overactivation of this process can have fatal con-
sequences for cardiac function, as we observed on SRSF3 
depletion. Post-transcriptional regulation plays an important 
role in heart disease, and several tools have been developed in 
recent years to modulate this process, most of them based on 
noncoding RNAs.44 A recent report showed that an inhibitor of 
Figure 7. SRSF3 (serine/arginine splicing factor 3) regulates mTOR (mammalian target of rapamycin) splicing, and its depletion induces decapping 
of contraction-related mRNAs. A, mTOR long and short isoforms. B, Western blot analysis of mTOR splicing isoforms and the phosphorylation states of 
AKT and 4E-BP1 in hearts of control and SRSF3 knockout (KO) mice on day 2 post tamoxifen induction. C–F, qRT-PCR (polymerase chain reaction) analysis 
of SERCA2A (C), RyR2 (D), MYBPC3 (E), and MYH7 (F) decapped mRNAs in hearts of tamoxifen-induced control and SRSF3 KO mice. Data are normalized 
to total mRNA expression and are shown as mean±SEM; n=5–9 mice per group. **P<0.01 and ***P<0.001 for SRSF3 KO vs Control; ##P<0.01 and 
###P<0.001 vs day 1; 2-way ANOVA followed by the Bonferroni post-test. 4E-BP1 indicates eIF4E-binding protein 1; eIF4E, eukaryotic translation initiation 
factor 4E; MYBPC3, myosin-binding protein C3; MYH7, myosin heavy chain 7; RYR2, ryanodine receptor 2; and SERCA2A, sarcoplasmic/endoplasmic 
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the mRNA decapping scavenger enzyme can improve spinal 
muscular atrophy,45 suggesting that this mRNA degradation 
mechanism could become an effective therapeutic target.
The finding that direct binding of SRSF3 to 3′-UTRs has 
no effect on mRNA stability suggested that SRSF3 likely regu-
lates mRNA degradation indirectly. The function of SRSF3 as 
a splicing regulator is widely known, and our results confirm 
this role in the heart. Binding to mTOR mRNA and regula-
tion of its alternative splicing was previously described for the 
RBP Sam68 during adipogenesis; however, that study did not 
detect the endogenous short mTOR protein isoform.46,47 Our 
results thus provide the first evidence for the protein expres-
sion of the endogenous mTOR short isoform, and ours is also 
the first study to describe this alternative splicing change in 
heart tissue. Interestingly, a previous iCLIP study also identi-
fied mTOR as a direct SRSF3 target in P19 cells.36 Although 
this finding was not explored further, taken together with our 
report, it suggests that SRSF3 may regulate mTOR splicing in 
several tissues. Moreover, SRSF3 binds a further 210 genes in 
both P19 cells and cardiomyocytes. These genes are involved 
Figure 8. Summary of SRSF3 (serine/arginine splicing factor 3) signaling in cardiomyocytes. SRSF3 regulates mTOR (mammalian target of rapamycin) 
splicing, promoting synthesis of the long isoform. This isoform phosphorylates 4E-BP1, preventing it from inhibiting interaction of eIF4E with the mRNA caps 
and the subsequent mRNA translation. In the absence of SRSF3, the short mTOR (mammalian target of rapamycin) isoform prevails, 4E-BP1 phosphorylation 
is reduced, and mRNA decapping increases, leading to its mRNA degradation. 4E-BP1 indicates eIF4E-binding protein 1; eIF4E, eukaryotic translation 
initiation factor 4E; MYBPC3, myosin-binding protein C3; MYH6, myosin heavy chain 6; MYH7, myosin heavy chain 7; RYR2, ryanodine receptor 2; and 
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in post-transcriptional mRNA processing and are enriched in 
nucleic acid binding proteins, suggesting that SRSF3 may reg-
ulate these processes in several cell types. In line with our re-
sults, loss of mTOR activity has been related to a decrease in 
5′-capped mRNA,48 and mTOR activity in the heart has been 
reported to be essential for proper cardiac function and sur-
vival.49 However, the phenotype of mTOR knockout mice dif-
fers from that of SRSF3 knockout mice. On cardiac mTOR 
depletion, mice develop dilated cardiomyopathy and survive 
for several weeks after tamoxifen treatment,49 whereas in our 
analysis cardiac SRSF3 depletion led to acute systolic dys-
function and animal death in <8 days after treatment. It is thus 
likely that SRSF3 knockout animals do not develop dilated car-
diomyopathy because there is insufficient time before they die. 
The phenotype of SRSF3 knockout mice is more aggressive 
than that of mTOR knockout mice, and hearts lacking SRSF3 
expression also undergo many other changes. It is thus possi-
ble that the observed phenotype involves contributions from 
additional molecular processes in which SRSF3 participates, 
not necessarily through alternative splicing. Alternatively, the 
mTOR short isoform could act as a dominant negative protein, 
precluding mTOR proper function and promoting decapping. 
We also cannot exclude the possibility that the increased de-
capping and mRNA degradation effects of mTOR deficiency 
may involve contributions from targets other than 4E-BP1. 
Furthermore, SRSF3 is involved in other biological process-
es that could potentially contribute to the severe phenotype 
observed in knockout mice. SRSF3 controls mRNA nuclear 
export and translation through a number of different mecha-
nisms, which has an impact on different biological processes, 
ranging from microglia activation to tumor cell apoptosis.11,18,50 
Although apoptosis and inflammation appear in SRSF3 knock-
out mice are unlikely to contribute to systolic dysfunction; they 
may aggravate the animals’ condition at late time points.
In conclusion, we have identified SRSF3 as an essential 
factor for proper heart contraction and animal survival. Loss 
of SRSF3 in the heart leads to a critical downregulation of 
contraction-related genes, most probably caused by induction 
of the decapping process. We have also shown that SRSF3 
regulates mTOR alternative splicing and presented the first 
report of the endogenous mTOR short isoform protein. This 
alternative splicing change leads to a dephosphorylation of 
4E-BP1 that would explain the induction of mRNA decapping 
(Figure 8). Given that SRSF3 expression is downregulated af-
ter MI, we propose both SRSF3 and mRNA decapping as key 
regulators of cardiac function, paving the way to new thera-
peutic approaches to treat heart disease.
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